Associated Papers
New Resources to Identify Characterized DNA Reference Materials for Pharmacogenetic (PGx) and Human Leukocyte Antigen (HLA) Testing: The Genetic Testing Reference Material (GeT-RM) Program PGx Search Tool and GeT-RM Consolidated PGx and HLA Table.
Scheinfeldt L et al.
The Journal of Molecular Diagnostics : Jmd, 2025
Pharmacogenomics and genetic ancestry in Colombia: a study on all variant drug annotations of PharmGKB.
Acosta-Monterrosa AA et al.
Frontiers in Pharmacology, 2025
A New Cloud-Native Tool for Pharmacogenetic Analysis.
Yuan DY et al.
Genes, 2024
Multi-center implementation of rapid whole genome sequencing provides additional evidence of its utility in the pediatric inpatient setting.
Thompson L et al.
Frontiers in Pediatrics, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Pharmacogenomic profiling of the South Korean population: Insights and implications for personalized medicine.
Youn MS et al.
Frontiers in Pharmacology, 2024
The effects of pathogenic and likely pathogenic variants for inherited hemostasis disorders in 140 214 UK Biobank participants.
Stefanucci L et al.
Blood, 2023
A Case of Unexplained Warfarin Resistance: A Case Report and Literature Review.
Favaedi M et al.
The Journal of Tehran Heart Center, 2023
Missense VKOR mutants exhibit severe warfarin resistance but lack VKCFD via shifting to an aberrantly reduced state.
Li S et al.
Blood Advances, 2023
Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population.
Goljan E et al.
Plos One, 2022
Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm.
Ndadza A et al.
Journal of Thrombosis and Haemostasis : Jth, 2021
Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.
Hirata TDC et al.
Molecular Diagnosis & Therapy, 2021
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multi-Ethnic Allele and Copy Number Variant Detection.
Scott SA et al.
Clinical and Translational Science, 2021
Multiplexed measurement of variant abundance and activity reveals VKOR topology, active site and human variant impact.
Chiasson MA et al.
Elife, 2020
Genotype-guided warfarin therapy: Still of only questionable value two decades on.
Shah RR
Journal of Clinical Pharmacy and Therapeutics, 2020
Comprehensive germline genomic profiles of children, adolescents and young adults with solid tumors.
Akhavanfard S et al.
Nature Communications, 2020
CYP2C9-mediated warfarin and milk thistle interaction.
Lash DB et al.
Journal of Clinical Pharmacy and Therapeutics, 2020
Added Value of Clinical Sequencing: WGS-Based Profiling of Pharmacogenes.
Caspar SM et al.
International Journal of Molecular Sciences, 2020
The Genetics of Warfarin Dose-Response Variability in Africans: An Expert Perspective on Past, Present, and Future.
Ndadza A et al.
Omics : a Journal of Integrative Biology, 2019
Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews.
Zhou Y et al.
Journal of Medical Genetics, 2018
Stabilization of warfarin-binding pocket of VKORC1 and VKORL1 by a peripheral region determines their different sensitivity to warfarin inhibition.
Shen G et al.
Journal of Thrombosis and Haemostasis : Jth, 2018
Bioequivalence Study of Warfarin in Healthy Chinese Volunteers With a Validated High-Performance Liquid Chromatography-Mass Spectrometry Method.
Li W et al.
Clinical Pharmacology in Drug Development, 2018
VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.
Mili FD et al.
Future Cardiology, 2018
Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting.
Kalman LV et al.
Clinical Pharmacology and Therapeutics, 2016
Warfarin resistance associated with genetic polymorphism of VKORC1: linking clinical response to molecular mechanism using computational modeling.
Lewis BC et al.
Pharmacogenetics and Genomics, 2016
Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2016
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics.
Duconge J et al.
Plos One, 2016
Structural Modeling Insights into Human VKORC1 Phenotypes.
Czogalla KJ et al.
Nutrients, 2015
[Resistance to acenocoumarol revealing a missense mutation of the vitamin K epoxyde reductase VKORC1: a case report].
Mboup MC et al.
Annales De Cardiologie Et D'angeiologie, 2015
Pharmacogenetics of coumarin anticoagulants in Brazilians.
Suarez-Kurtz G et al.
Expert Opinion on Drug Metabolism & Toxicology, 2015
A Proposal for an Individualized Pharmacogenetic-Guided Warfarin Dosage Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy.
Bosch LA
Journal of Pharmacogenomics & Pharmacoproteomics, 2014
Pharmacogenetics in Jewish populations.
Yang Y et al.
Drug Metabolism and Drug Interactions, 2014
Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses.
Ohara M et al.
Plos One, 2014
Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces.
Czogalla KJ et al.
Blood, 2013
Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.
Kadian-Dodov DL et al.
Vascular Medicine (london, England), 2013
Pharmacogenomics of warfarin in populations of African descent.
Suarez-Kurtz G et al.
British Journal of Clinical Pharmacology, 2013
VKORC1 mutations detected in patients resistant to vitamin K antagonists are not all associated with a resistant VKOR activity.
Hodroge A et al.
Journal of Thrombosis and Haemostasis : Jth, 2012
Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients.
Pathare A et al.
Journal of Human Genetics, 2012
Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction.
Kurnik D et al.
Thrombosis and Haemostasis, 2012
Optimization of warfarin dose by population-specific pharmacogenomic algorithm.
Pavani A et al.
The Pharmacogenomics Journal, 2012
Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes.
Valentin II et al.
The Annals of Pharmacotherapy, 2012
Novel VKORC1 mutations associated with warfarin sensitivity.
Baniasadi S et al.
Cardiovascular Therapeutics, 2011
Exacerbation of hereditary warfarin resistance by azathioprine.
Pushpakom SP et al.
Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/hemostasis, 2011
Pharmacogenetics, pharmacogenomics, and individualized medicine.
Ma Q et al.
Pharmacological Reviews, 2011